Use of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection

Similar documents
Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer

Sentinel Lymph Node Biopsy for Breast Cancer

Practice of Axilla Surgery

Results of the ACOSOG Z0011 Trial

Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial

Is Sentinel Node Biopsy Practical?

16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes

PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT

Radionuclide detection of sentinel lymph node

Relevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged:

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest

Prediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath

EDITORIAL. Ann Surg Oncol (2011) 18: DOI /s

Evaluation of the Axilla Post Z-0011 Trial New Paradigm

Sentinel Lymph Node Detection in Early Carcinoma Breast: A Comparative Study Between Intralesional and Perilesional Dye Injection

The Role of Sentinel Lymph Node Biopsy and Axillary Dissection

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy

Sentinel Node Biopsy, Introduction and Application of the Technique in a Senology Unit of a District Hospital - Prospective Study.

EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY

Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Sentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner

Breast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016

Results, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de

Updates on management of the axilla in breast cancer the surgical point of view

Targeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center

Clinical outcomes after sentinel lymph node biopsy in clinically node-negative breast cancer patients

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Melanoma Quality Reporting

Pathology Report Patient Companion Guide

BREAST CANCER SURGERY. Dr. John H. Donohue

Ultrasound or FNA for Predicting Node Positive in Breast Cancer

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

At many centers in the United States and worldwide,

Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study

Implication of 18 F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact

Axillary Reverse Mapping to Reduce the Incidence of Lymphedema

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

Department of General Surgery, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

Review Article Controversial Indications for Sentinel Lymph Node Biopsy in Breast Cancer Patients

Appropriate Concept of Prevention of Lymphedema at the Initial Treatment

COMPARATIVE ANALYSIS OF COLON AND RECTAL CANCERS IN SENTINEL LYMPH NODE MAPPING

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy

Recent Update in Surgery for the Management of Breast Cancer

Northumbria Healthcare NHS Foundation Trust. Breast Sentinel Lymph Node Biopsy. Issued by the Breast Team

SPECT/CT Imaging of the Sentinel Lymph Node

PAPER. Long-term Outcome of Patients Managed With Sentinel Lymph Node Biopsy Alone for Node-Negative Invasive Breast Cancer

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD

ORIGINAL ARTICLE BREAST ONCOLOGY. Ann Surg Oncol (2010) 17: DOI /s x

Rebecca Vogel, PGY-4 March 5, 2012

Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?

Advances in Localized Breast Cancer

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients

The evaluation of sentinel lymph nodes (SLNs) in the

Evaluating the Z011 study and how local-regional therapy for early breast cancer may change

Jianyi Li, Shi Jia, Wenhai Zhang *, Fang Qiu, Yang Zhang, Xi Gu and Jinqi Xue

Canadian Scientific Journal. Intraoperative color detection of lymph nodes metastases in thyroid cancer

Feasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel lymph node metastasis in breast cancer patients

PAPER. Relapse and Morbidity in Patients Undergoing Sentinel Lymph Node Biopsy Alone or With Axillary Dissection for Breast Cancer

ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA

Correlation of Imprint Cytology of Axillary Lymph Nodes in Breast Carcinoma with the Histopathological Diagnosis

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

M D..,., M. M P.. P H., H, F. F A.. A C..S..

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer

Evolution of Breast Surgery

NICE diagnostics guidance on intraoperative tests (RD 100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

ALND. Dr. MJ Vrancken

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins

The right middle lobe is the smallest lobe in the lung, and

Maria João Cardoso, MD, PhD

The Value of Intraoperative Examination of Axillary Sentinel Nodes in Carcinoma of the Breast.

Controversies and Questions in the Surgical Treatment of Melanoma

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy

ORIGINAL ARTICLE. Characteristics of the Sentinel Lymph Node in Breast Cancer Predict Further Involvement of Higher-Echelon Nodes in the Axilla

Removal of sentinel lymph node(s)

Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective

Abstract 80 DCIS Treated With Excision Alone Using the National Comprehensive Cancer Network (NCCN) Guidelines

The Clinical Value of Axillary Ultrasonography for Detection of Axillary Lymph Node Metastasis in Cases with Breast Cancer

Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy

Breast Cancer. Saima Saeed MD

Correspondence should be addressed to Donald R. Lannin;

Ines Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM

Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast

Outcome after emergency surgery in patients with a free perforation caused by gastric cancer

Breast Imaging. Jamie L. Wagner, DO, FACOS. Digital vs Analog Mammography (2-D) Surgical Oncologist. Patient with Cancer. Radiology/ Interventional

How can surgeons help the Radiation Oncologists?

Sentinel Lymph Node Biopsy in Other Tumours: Sentinel Lymph Node Biopsy in Other Tumours. Methodology. Results. Key Questions to Consider

A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer

Prospective study found that peripheral lymph node sampling reduced the false negative rate of sentinel lymph node biopsy for breast cancer

Transcription:

456 Use of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection TOMOKO TAKAMARU 1, GORO KUTOMI 1, FUKINO SATOMI 1, HIROAKI SHIMA 1, KEISUKE OHNO 1, HIDEKAZU KAMESHIMA 1, YASUYO SUZUKI 1, TOUSEI OHMURA 1, HIROYUKI TAKAMARU 2, MASANORI NOJIMA 3, MITSURU MORI 3 and KOICHI HIRATA 1 1 First Department of Surgery and 2 First Department of Internal Medicine, Sapporo Medical University, Sapporo, Hokkaido 060 8543; 3 Department of Public Health, Sapporo Medical University, Sapporo, Hokkaido 060 8556, Japan Received June 19, 2013; Accepted October 21, 2013 DOI: 10.3892/etm.2013.1445 Abstract. For sentinel lymph node biopsy (SLNB), a combination of dye guided and γ probe guided methods is the most commonly used technique. However, the number of institutes in which the γ probe guided method is able to be performed is limited, since special equipment is required for the method. In this study, SLNB with the dye guided method alone was evaluated, and the clinicopathological characteristics were analyzed to identify any factors that were predictive of whether the follow up axillary lymph node dissection (ALND) was able to be omitted. A total of 374 patients who underwent SLNB between 1999 and 2009 were studied. The SLN identification rate was analyzed, in addition to the false positive and false negative rates and the correlation between the clinicopathological characteristics and axillary lymph node metastases. The SLN was identified in 96.8% of cases, and, out of the patients who had SLN metastasis, 63.0% did not exhibit metastasis elsewhere. The sensitivity was 96.4% and the specificity was 100%. The false negative rate was 3.6%. Univariate analyses revealed significant differences in the lymph vessel invasion (ly) status, nuclear grade (NG), maximum tumor size and the percentage of the area occupied by the tumor cells in the SLN (SLN occupation ratio) between the patients with and without non SLN metastasis, indicating that these factors may be predictive of axillary lymph node metastasis. Multivariate analysis revealed that ly status was an independent risk factor for non SLN metastasis. In conclusion, SLN with the dye guided method alone provided a high detection rate. The Correspondence to: Professor Koichi Hirata, First Department of Surgery, Sapporo Medical University, South 1 West 16, Chuo ku, Sapporo, Hokkaido 060 8543, Japan E mail: fujikane@sapmed.ac.jp Key words: axillary lymph node dissection, breast cancer, dye guided method, sentinel lymph node biopsy, prediction of lymph node metastasis study identified a predictive factor for axillary lymph node metastasis that may improve the patients' quality of life. Introduction Αxillary lymph node dissection (ALND) provides information for staging and prognosis that may be used to design a therapeutic strategy (1 3). As a result of this, a large number of patients with breast cancer in the past underwent routine ALND; however, in many of the patients, the cancer was revealed to be node negative, and surgery unnecessarily exposed them to perioperative risks and increased long term morbidity (4). Therefore, sentinel lymph node biopsy (SLNB) has widely replaced conventional ALND as a routine axillary staging method in breast cancer surgery. The SLNB procedure is accurate and safe (5 8) and results in substantially less postoperative morbidity than ALND (9,10). Dye guided and γ probe guided methods, separately and in combination, are used for SLNB. The dye guided method alone for breast cancer is considered to be inferior to the γ probe guided and combined methods in terms of its accuracy and false negative rate. Cox et al (11) revealed the identification rates for SLNB to be 80.3% for the dye guided technique, 88.6% for the γ probe guided method and 96.7% for the combination, based on a large number of procedures performed in a single center. Kim et al (12) showed that the rates for successfully identifying the SLN were 83.1, 89.2 and 91.9%, for the dye guided alone, γ probe guided alone and combination methods, respectively [with the combination method being significantly more efficacious (P=0.007)], while the false negative rates were 10.9, 8.8 and 7.0%, respectively (P=0.047). The dye guided method has the significant advantages of being more convenient to perform, less costly and possible to conduct in any institute with no special facilities. Although it requires a certain training period, this method may be preferable for all clinicians if its accuracy is demonstrated to be comparable to that of the combination method. Morrow et al (13) reported that there were no significant differences between the procedures with regard to the identifi-

TAKAMARU et al: SENTINEL LYMPH NODE BIOPSY GUIDED BY DYE ALONE 457 cation rate, accuracy, time spent for identification and number of SLNs. In the present study, the success rate in identifying the SLN, the accuracy and the SLN occupation ratio using the dye guided method alone were investigated. Furthermore, the possibility of obviating the requirement for ALND in SLNB positive cases was explored. Materials and methods Patients. From January 1999 to December 2009, 374 patients with primary breast cancer underwent SLNB using the dye guided method alone followed by radical surgery at Sapporo Medical University Hospital (Sapporo, Japan). The medical records of these patients were analyzed retrospectively and their clinicopathological characteristics were evaluated. This study was approved by The Ethics Committee of Sapporo Medical University (Sapporo, Japan). Informed consent was obtained from all patients prior to enrollment. Surgical procedure. Under general anesthesia, 2 4 ml blue dye (indigo carmine) was injected at two sites surrounding the primary tumor and areola. Approximately 5 min later, a blunt dissection was performed through the mastectomy incision or a separate axillary incision until a dye stained lymphatic tract or node was identified. Pathological assessment. The SLN was split into three to four sections and analyzed as frozen specimens during surgery. These specimens were fixed in 10% formalin, stained with hematoxylin and eosin (H&E) and then re examined histologically following surgery. The SLN area and the area of tumor cells in the SLN were calculated by multiplying the longest diameter by the minor axis. The SLN occupation ratio was defined as the proportion of area that was occupied by tumor cells to the total SLN area. As a feasibility study, ALND was completed for cases of at least level I or II following SLN excision in the first 54 cases to undergo surgery. Statistical analysis. Continuous variables (age, maximum tumor size and SLN occupation ratio), dichotomous variables (estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 status) and categorical variables [lymph vessel invasion (ly) status, vessel invasion (v) status and nuclear grade (NG)] were analyzed in a univariate logistic regression model using either the t test or the χ 2 test. All variables were subsequently analyzed in a multivariable regression model. A receiver operating characteristic (ROC) curve was drawn on the basis of the SLN occupation ratio, and the area under the curve (AUC) was calculated using SPSS version 11.5 statistical software (SPSS, Inc., Chicago, IL, USA). GraphPad Prism version 5.0.2 (GraphPad Software, La Jolla, CA, USA) was used for all analyses. P<0.05 was considered to indicate a statistically significant difference. Results The clinicopathological characteristics of the patients are shown in Table I. The SLN was successfully identified in 362 of the 374 patients (96.8%). The average number of resected lymph nodes was 1.9 (range, 1 10). A total of 54 patients were Table I. Characteristics of 374 patients who underwent SLNB. Clinical features No. of patients (%) Mean age, years (range) 56.7 (23 87) Location of tumor Medial 103 (27.5) Lateral 264 (70.6) Central 7 (1.9) Clinical tumor stage T0 14 (3.7) T1 175 (46.8) T2 161 (43.0) T3 19 (5.1) T4 5 (1.3) Clinical nodal stage N0 332 (88.8) N1 41 (11.0) N2 1 (0.3) N3 0 (0.0) No. of SLN 1 149 (39.8) 2 130 (34.8) 3 56 (15.0) 4 18 (4.8) 5 9 (2.4) Not detected 12 (3.2) SLNB, sentinel lymph node biopsy. identified to have SLN metastases and ALND was performed in these patients. In 34 of the 54 patients (63.0%) with axillary metastases, metastatic nodes were only observed in the SLN. In the remaining 20 patients (37.0%), metastases were observed in the SLN and the non SLNs. Of the 308 patients without SLN metastases in the frozen sections, 49 underwent ALND. Two of these 49 had positive axillary lymph nodes in the formalin fixed sections. Among the 259 patients who did not undergo ALND, six had positive formalin fixed sections (Fig. 1). Postoperative diagnosis of SLN metastases. The sensitivity for the identification of a histologically positive node was 96.4% (54/56) (Table IIA), and the specificity was 100%. The accuracy of SLN biopsy for the detection of metastatic disease was 98.1% (101/103). The positive predictive value was 100% (54/54) and the negative predictive value (the correlation between the negative SLNs and the negative axillary nodes) was 95.9% (47/49), with a false negative rate of 3.6% (2/56). Intraoperative diagnosis of SLN metastases. In 362 patients, the intraoperative diagnosis was confirmed by the final histological examination (with formalin fixed specimens). However, in eight patients (12.9%) there was a false negative intraoperative diagnosis and a tumor was identified on a

458 Table II. Diagnosis of sentinel lymph node metastases. A. Postoperative diagnosis Postoperative diagnosis SLN or non SLN-positive SLN and non SLN-negative Total SLN-positive 54 0 54 SLN-negative 2 47 49 Total 56 47 103 B. Intraoperative diagnosis Intraoperative diagnosis SLN-positive SLN-negative Total SLN-positive 54 0 54 SLN-negative 8 300 308 Total 62 300 362 Postoperative diagnosis: The sensitivity for sentinel lymph node (SLN) metastasis was 96.4%, the specificity was 100% and the false negative rate was 3.6%. Intraoperative diagnosis: A diagnostic accuracy of 97.8%, a sensitivity of 87.1% and specificity of 100% were achieved with hematoxylin and eosin (H&E) staining in the frozen sections; the false negative rate was 12.9%. Figure 1. Patient status. SLNB, sentinel lymph node biopsy; SLN, sentinel lymph node; ALND, axillary lymph node dissection. permanent section of either the SLN or the non SLNs. As a result, a diagnostic accuracy of 97.8%, a sensitivity of 87.1% and a specificity of 100% were achieved with H&E staining of the frozen sections (Table IIB). Clinicopathological factors correlated with non SLN metastasis. In 63% of the SLN positive cases for which ALND was performed, metastasis was limited to the SLN. This result suggested the possibility that the resection of SLNs only may be sufficient to treat in excess of half of the cases with positive SLNs. Therefore, the cases were analyzed to reveal which factors were likely to indicate the potential for omitting the following ALND. To investigate which factors correlated with non SLN metastasis, the clinicopathological characteristics of the patients who underwent ALND and had SLN and non SLN metastases were compared with those who underwent ALND and just had SLN metastasis. Univariate analyses revealed significant differences in the ly status (P=0.0002), NG (P=0.0433), maximum tumor size (P=0.0317) and the SLN occupation rate (P=0.0017) between the two groups. The results of the analyses for various characteristics are summarized in Table III. Multivariate analysis revealed that ly status was an independent risk factor for non SLN metastasis (Table IV). An ROC curve was generated to assess the clinical utility of the SLN occupation ratio for the prediction of non SLN metastasis (sensitivity, 70.0%; specificity, 61.8%; AUC, 0.736). Axillary recurrences. In this study group, 5 out of the total 374 cases (1.3%) had an axillary recurrence. Out of all the patients, 259 patients received SLNB alone and 4/259 patients (1.5%) showed axillary recurrence. By contrast, patients who received ALND had no axillary recurrence. The SLN was not able to be detected in 12 cases, and axillary recurrence was observed in one of these cases.

TAKAMARU et al: SENTINEL LYMPH NODE BIOPSY GUIDED BY DYE ALONE 459 Table III. Clinicopathological factors correlated with non SLN metastasis. SLN and Clinical feature SLN only non SLN P value Mean age (years) 59.76 59.85 0.9820 Tumor size (cm) 2.34 2.92 0.0317 a ly ly0 12 0 ly1 3 20 20 Discussion 0.0002 b v 0.2346 v0 29 15 v1 3 5 NG 1 20 6 2 3 11 12 Unknown 3 2 0.0433 a ER status 0.7208 Negative 7 3 Positive 24 17 PgR status Negative 10 2 0.0949 Positive 21 18 HER2 status 0.6958 Negative 27 16 Positive 4 4 SLN occupation ratio (%) 21.47 46.75 0.0017 b P values were calculated using either the t test or the χ 2 test. a P<0.05, b P<0.01. SLN, sentinal lymph node; ly, lymph vessel invasion; v, vessel invasion; NG, nuclear grade; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor type 2; SLN occupation ratio, percentage of SLN area occupied by tumor cells. In the present study, the SLN identification rate with the dye guided method alone was 97%, which was comparable with previous studies (11,12). The population of patients who had SLN metastasis was also consistent with those of previous studies. These data indicated that the dye guided method alone was sufficient to detect SLN metastasis. In addition, the dye guided method requires no special equipment, so widespread application may be expected in any institute. In SLN metastasis positive cases, subsequent ALND is generally performed. However, in the group observed in the present study, 63% of the patients had no axillary metastasis. These results may indicate that in excess of half the patients receive unnecessary additional surgery. In the management of breast cancer, ALND may dam up the flow of lymph vessels Table IV. Multivariate analysis. Risk factor for Relative SLN metastasis P value risk 95% CI Age 0.0938 1.00 0.93 1.07 Maximum tumor size 0.1477 2.09 0.81 8.24 ly ly0 0.0138 a 1.00 1.95 5.14x10 19 ly1 3 7.08x10 8 v v0 0.4950 1.00 0.27 20.47 v1 2.03 NG 1 0.1258 1.00 0.68 29.32 2 3 4.05 ER status Negative 0.8965 1.00 0.105 12.33 Positive 1.16 PgR status Negative 0.0823 1.00 0.791 145.56 Positive 7.30 HER2 status Negative 0.2760 1.00 0.43 25.07 Positive 3.00 a P<0.05. SLN, sentinel lymph node; CI, confidence interval; ly, lymph vessel invasion; v, vessel invasion; NG, nuclear grade; ER, estrogen receptor; PgR, progesteron receptor; HER2, human epidermal growth factor type 2. and result in lymphedema in the patient's arm. Although breast cancer is a malignant disease, survival may be relatively long subsequent to the first surgical therapy, so it is important to support the patient's quality of life (QOL). The possibility of predicting axillary lymph node metastasis by the analysis of the SLN status was investigated. The aim of identifying the factors that predict axillary metastasis was to contribute to avoiding unnecessary ALND. Univariate analysis revealed significant differences in ly status, NG, maximum tumor size and the SLN occupation ratio between patients with axillary metastasis and those with SLN metastasis only. In breast cancer, lymph node metastasis may spread through the lymph nodes stepwise, following the lymph vessel route. Thus, ly status, NG, tumor size and the SLN occupation ratio are associated with axillary metastasis, and the analysis of these factors is likely to enhance our capability to predict the patients with axillary lymph node metastasis. The multivariate analysis of the clinicopathological factors, including those mentioned previously, revealed a correlation between axillary metastasis and ly status. However, since it is necessary to assess these factors in permanent formalin fixed specimens, it is difficult to use them to decide on the surgical procedure during the surgery itself. Therefore, in the present study, the clinical usefulness of the SLN occupation ratio, which is able to be diagnosed during surgery, was investi-

460 gated. It was demonstrated that the greater the degree of the area occupied by tumor cells, the more invasive the tumor was to lymph vessels, with greater proliferative ability, a larger number of malignant cells, a more metastatic character, and the longer the time after metastasis. Thus, this parameter was expected to be correlated with axillary metastasis. The ROC curve analysis showed sufficient sensitivity and specificity (70.0 and 61.8%, respectively) when the cut off point for deciding whether it was necessary to perform ALND for patients who may not actually have axillary lymph node metastasis was 12.9%. Thus, a predictive factor for axillary lymph node metastasis in breast cancer was identified, which suggests that it may be possible to avoid unnecessary axillary lymph node resection, and thereby improve the patients' QOL. References 1. Senofsky GM, Moffat FL Jr, Davis K, et al: Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 126: 1336 1342, 1991. 2. Fentiman IS and Mansel RE: The axilla: not a no go zone. Lancet 337: 221 223, 1991. 3. Noguchi M, Miwa K, Michigishi T, et al: The role of axillary lymph node dissection in breast cancer management. Breast Cancer 4: 143 153, 1997. 4. Kissin MW, Querci della Rovere G, Easton D, et al: Risk of lymphoedema following the treatment of breast cancer. Br J Surg 73: 580 584, 1986. 5. Cox C, White L, Allred N, et al: Survival outcomes in node negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol 13: 708 711, 2006. 6. Kuijt GP, van de Poll Franse LV, Voogd AC, et al: Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection. Eur J Surg Oncol 33: 832 837, 2007. 7. Langer I, Guller U, Hsu Schmitz SF, et al: Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol 35: 805 813, 2009. 8. van der Ploeg IM, Nieweg OE, van Rijk MC, et al: Axillary recurrence after a tumour negative sentinel node biopsy in breast cancer patients: a systematic review and meta analysis of the literature. Eur J Surg Oncol 34: 1277 1284, 2008. 9. Lucci A, McCall LM, Beitsch PD, et al: Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25: 3657 3663, 2007. 10. Celebioglu F, Perbeck L, Frisell J, et al: Lymph drainage studied by lymphoscintigraphy in the arms after sentinel node biopsy compared with axillary lymph node dissection following conservative breast cancer surgery. Acta Radiol 48: 488 495, 2007. 11. Cox CE, Bass SS, McCann CR, et al: Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. Annu Rev Med 51: 525 542, 2000. 12. Kim T, Giuliano AE and Lyman GH: Lymphatic mapping and sentinel lymph node biopsy in early stage breast carcinoma: a metaanalysis. Cancer 106: 4 16, 2006. 13. Morrow M, Rademaker AW, Bethke KP, et al: Learning sentinel node biopsy: result of a prospective randomized trial of two techniques. Surgery 126: 714 722, 1999.